Sign In
Buy CNSP
$5.24
+0.320 (+6.50%)
At Close: Jun 03, 2026
CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement
09:00am, Thursday, 12'th Sep 2024
HOUSTON, TX / ACCESSWIRE / September 12, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for pr
CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
09:05am, Wednesday, 04'th Sep 2024
HOUSTON, TX / ACCESSWIRE / September 4, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for pri
IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc.
08:00am, Tuesday, 03'rd Sep 2024
LOS ANGELES, Sept. 03, 2024 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce t
CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
09:10am, Tuesday, 27'th Aug 2024
Live webcast on Wednesday, August 28th at 3:20 PM ET HOUSTON, TX / ACCESSWIRE / August 27, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company speciali
CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment
09:15am, Thursday, 22'nd Aug 2024
Live moderated webcast with John Climaco, Chief Executive Officer of CNS Pharmaceuticals on Monday, August 26th at 12:00 PM ET Participants have the ability to submit questions live during the Q&A por
CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results
08:00am, Thursday, 15'th Aug 2024
Potentially pivotal GBM study evaluating lead program, Berubicin, enrollment completed; Topline data expected in the first half of 2025 Recent strategic in-license of TPI 287 is highly synergistic wit
Why Is CNS Pharmaceuticals (CNSP) Stock Down 69% Today?
12:03pm, Tuesday, 30'th Jul 2024
CNS Pharmaceuticals (NASDAQ: CNSP ) stock is heading lower on Tuesday after the clinical-pharmaceutical company announced an expansion to its pipeline. CNS Pharmaceuticals has acquired an exclusive li
Strategic in-license from Cortice Bioscience is highly synergistic with the ongoing potentially pivotal Berubicin program and demonstrates further commitment to changing the treatment paradigm in GBM
CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference
09:05am, Thursday, 25'th Jul 2024
HOUSTON, TX / ACCESSWIRE / July 25, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary
CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series
09:15am, Tuesday, 16'th Jul 2024
Live video webcast with Chief Executive Officer, John Climaco, on Wednesday, June 17th at 4:00 PM ET HOUSTON, TX / ACCESSWIRE / July 16, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "C
CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement
11:10am, Wednesday, 03'rd Jul 2024
HOUSTON, TX / ACCESSWIRE / July 3, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary
CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement
08:00am, Wednesday, 26'th Jun 2024
HOUSTON, TX / ACCESSWIRE / June 26, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary
CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement
03:11pm, Friday, 14'th Jun 2024
HOUSTON, TX / ACCESSWIRE / June 14, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary
CNS Pharmaceuticals Announces Reverse Stock Split
08:05am, Monday, 03'rd Jun 2024
HOUSTON, TX / ACCESSWIRE / June 3, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary
CNS Pharmaceuticals Reports First Quarter 2024 Financial Results
07:45am, Thursday, 16'th May 2024
Enrollment completed in potentially pivotal GBM study evaluating Berubicin; Topline data expected in first half of 2025 Company committed to addressing the most aggressive type of brain cancer with an
